This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sugar, A. M.
Right arrow Articles by McCaffrey, R. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sugar, A. M.
Right arrow Articles by McCaffrey, R. P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 1998, p. 1424-1427, Vol. 42, No. 6
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Antifungal Activity of 3'-Deoxyadenosine (Cordycepin)dagger

Alan M. Sugar* and Ronald P. McCaffrey

Evans Memorial Department of Clinical Research, Boston Medical Center, and Department of Medicine, Boston University School of Medicine, Boston, Massachusetts

Received 29 January 1998/Returned for modification 5 March 1998/Accepted 6 April 1998

The antifungal activity of the nucleoside analog 3'-deoxyadenosine (cordycepin) was studied in a murine model of invasive candidiasis. When protected from deamination by either deoxycoformycin or coformycin, both of which are adenosine deaminase inhibitors, cordycepin exhibited potent antifungal efficacy, as demonstrated by prolongation of survival and a decrease in CFU in the kidneys of mice treated with cordycepin plus an adenosine deaminase inhibitor. The antifungal effect was seen with three different Candida isolates: Candida albicans 64, a relatively fluconazole-resistant clinical isolate of C. albicans (MIC, 16 µg/ml), and the fluconazole-resistant Candida krusei. Cordycepin and related compounds may provide another avenue for the discovery of clinically useful antifungal drugs.

* Corresponding author. Mailing address: Boston Medical Center, E336, 88 E. Newton St., Boston, MA 02181. Phone: (617) 638-7905. Fax: (617) 638-8070. E-mail: asugar{at}med-med1.bu.edu.

dagger Publication no. 011 from the Collaborative Medical Mycology Program (Pfizer Inc., Roerig Division; Phytera; Scriptgen Pharmaceuticals; and Section of Infectious Diseases, Boston Medical Center).

Antimicrobial Agents and Chemotherapy, June 1998, p. 1424-1427, Vol. 42, No. 6
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Holbein, S., Wengi, A., Decourty, L., Freimoser, F. M., Jacquier, A., Dichtl, B. (2009). Cordycepin interferes with 3' end formation in yeast independently of its potential to terminate RNA chain elongation. RNA 15: 837-849 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»